Pharmaceutical products

Description

NHS Pharmaceuticals 2017_1 Offer reference number: CM/PHG/15/5490 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months. Potential periods of call-offs under the framework agreement: North West and Eastern and North London: 1.5.2017 to 31.1.2018 (9 months), South East and South London and North East and Yorkshire: 1.5.2017 to 31.10.2017 (6 months), Central and South West: 1.5.2017 to 30.6.2018 (14 months). NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months. Potential periods of call-offs under the framework agreement: CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months), CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months), CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months). NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months. Potential periods of call-offs under the framework agreement: CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months), CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months), CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months). NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months. Potential periods of call-offs under the framework agreement: CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months), CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months), CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months).